Centers for Disease Control and Prevention, CDC Surveillance Summaries, Morbidity and Mortality Weekly Report 1998;47(SS-1).

CDC, Forecasted state-specific estimates of self-reported asthma prevalence – United States, 1998; MMWR 1998;47(47):1022-1025.

CDC, Vital and Health Statistics, Current estimates from the National Health Interview Survey, 1994 (U.S. Department of Health and Human Services, Public Health Service, National Center for Health Statistics) 1995;DHHS Pub. No. PHS 96-1521.

Ebner C, Siemann U, Bohle B, et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997; 27:1007-1015.

Gergen PJ, Turkeltaub PC, Kaovar MG. The prevalence of allergic skin reactivity to eight common allergens in the U.S. population: results from the second National Health and Nutrition Examination Survey. J Allergy Clin Immunol 1987;800:669-79.

Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children – a 14-year study. Pediatrics 1968;42:793-802.

Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251-6.

National Heart, Lung, and Blood Institutes, U.S. Department of Health and Human Services, Public Health Service, and National Institutes of Health 1990:NIH Pub. No. 90-2339.

Ross RN, et al. Effectiveness of specific immunotherapy in the treatment of Hymenoptera venom hypersensitivity. Clin Ther 2000;22 (Suppl):351-58.

Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin Ther 2000;22(Suppl):329-341.